Brilinta

Chemical Nameticagrelor
Dosage FormTablet (oral; 60 mg, 90 mg)
Drug ClassP2Y12 platelet inhibitors
SystemBlood
CompanyAstraZeneca
Approval Year2011

Indication

  • Indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI.
  • Indicated to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events.
  • Indicated to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA).
Document TitleYearSource
Brilinta (ticagrelor) Prescribing Information.2022AstraZeneca Pharmaceuticals LP, Wilmington, DE
Document TitleYearSource
Efficacy and safety of de-escalation of antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome: a meta-analysis of randomized clinical trials.2022Journal of Cardiovascular Pharmacology
Efficacy and safety of clopidogrel versus ticagrelor as part of dual antiplatelet therapy in acute coronary syndrome - a systematic review and meta-analysis.2022Journal of Cardiovascular Pharmacology
Comparison of clinical outcomes between ticagrelor and clopidogrel in acute coronary syndrome: a comprehensive meta-analysis.2022Frontiers in Cardiovascular Medicine
Systematic review of drug-drug interactions between rifamycins and anticoagulant and antiplatelet agents and considerations for management.2022Pharmacotherapy
Comparison of prasugrel and ticagrelor for patients with acute coronary syndrome: a systematic review and meta-analysis.2022Cardiology
Effect of CYP2C19 genetic polymorphism on the pharmacodynamics and clinical outcomes for patients treated with ticagrelor: a systematic review with qualitative and quantitative meta-analysis. 2022BMC Cardiovascular disorders
Comparison of ticagrelor with clopidogrel in East Asian patients with acute coronary syndrome: a systematic review and meta-analysis of randomized clinical trials.2022Journal of Cardiovascular Pharmacology
P2Y12 inhibitors plus aspirin for acute treatment and secondary prevention in minor stroke and high-risk transient ischemic attack: a systematic review and meta-analysis.2022European Journal of Internal Medicine
Comparison of ticagrelor vs clopidogrel in addition to aspirin in patients with minor ischemic stroke and transient ischemic attack: a network meta-analysis.2022JAMA Neurology
Ticagrelor versus clopidogrel in East Asian patients with acute coronary syndrome: a meta-analysis.2022Frigid Zone Medicine
Acute coronary syndrome and renal impairment: a systematic review. 2022Reviews in Cardiovascular Medicine
Impact of prasugrel and ticagrelor on platelet reactivity in patients with acute coronary syndrome: a meta-analysis.2022Frontiers in Cardiovascular Medicine
P2Y12 receptor inhibitor plus aspirin versus aspirin treated within 24 hours of acute noncardioembolic ischemic stroke or TIA: meta-analysis.2022Journal of the Formosan Medical Association
Early vs. delayed initiation of treatment with P2Y12 inhibitors in patients with non-ST-segment elevation acute coronary syndrome: a systematic review and network meta-analysis of randomized controlled trials.2022Frontiers in Cardiovascular Medicine
Comparison of prasugrel and ticagrelor for patients with acute coronary syndrome: a systematic review and meta-analysis.2022Cardiology
Comparative efficacy and safety of antiplatelet or anticoagulant therapy in patients with chronic coronary syndromes after percutaneous coronary intervention: a network meta-analysis of randomized controlled trials.2022Frontiers in Pharmacology
Optimal duration and combination of antiplatelet therapies following percutaneous coronary intervention: a meta-analysis.2021Vascular Pharmacology
Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. 2021European Heart Journal
Effect of CYP2C19 genotype on ischemic outcomes during oral P2Y12 inhibitor therapy: a meta-analysis.2021JACC: Cardiovascular Interventions
De-escalation from prasugrel or ticagrelor to clopidogrel in patients with acute coronary syndrome managed with percutaneous coronary intervention: an updated meta-analysis of randomized clinical trials.2021American Journal of Cardiovascular Drugs
De-escalation of dual antiplatelet therapy in patients with acute coronary syndromes.2021Journal of the American College of Cardiology
Guided versus standard antiplatelet therapy in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis.2021The Lancet
Antiplatelet drugs for secondary prevention in patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis.2021BMC Neurology
Efficacy and safety of using dual versus monotherapy antiplatelet agents in secondary stroke prevention: systematic review and meta-analysis of randomized controlled clinical trials.2021Circulation
Antiplatelet regimens for Asian patients with ischemic stroke or transient ischemic attack: a systematic review and network meta-analysis.2021Annals of Translational Medicine
Comparison of major bleeding in patients with acute coronary syndrome that underwent coronary artery bypass grafting treated with clopidogrel or ticagrelor: a systematic review and meta-analysis.2021F1000Research
Efficacy and safety of ticagrelor monotherapy in patients following percutaneous coronary intervention.2021Medicine
Efficacy and safety of low dose ticagrelor in patients with acute coronary syndrome: a systematic review and meta-analysis.2020Postgraduate Medical Journal
Prasugrel vs ticagrelor for DAPT therapy in patients with ACS undergoing PCI: a systematic review and meta-analysis of randomized controlled trials.2020Cardiovascular Revascularization Medicine
Ticagrelor for the primary prevention of stroke in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials.2020Journal of Thrombosis and Thrombolysis
Risk of bradyarrhythmia related to ticagrelor: a systematic review and meta-analysis.2020Pharmacological Research
Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis.2020BMC Cardiovascular Disorders
Prasugrel versus ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a systematic review and meta-analysis of randomized trials.2020Cardiovascular Drugs and Therapy
The risk of dyspnea in patients treated with third-generation P2Y12 inhibitors compared with clopidogrel: a meta-analysis of randomized controlled trials.2020BMC Cardiovascular Disorders
P2Y 12 inhibitors with oral anticoagulation for percutaneous coronary intervention with atrial fibrillation: a systematic review and meta-analysis.2020Heart
Efficacy and safety of newer P2Y12 inhibitors for acute coronary syndrome: a network meta‑analysis.2020Scientific Reports
Efficacy and safety of ticagrelor compared to clopidogrel in patients undergoing percutaneous coronary intervention: a meta-analysis.2019Current Pharmaceutical Design
Comparisons between ticagrelor and clopidogrel following percutaneous coronary intervention in patients with acute coronary syndrome: a comprehensive meta-analysis.2019Drug Design, Development and Therapy
Prasugrel vs. ticagrelor for acute coronary syndrome patients undergoing percutaneous coronary intervention: a systematic review and meta‑analysis.2019American Journal of Cardiovascular Drugs
Choosing between ticagrelor and clopidogrel following percutaneous coronary intervention.2018Medicine
Ticagrelor for stroke prevention in patients with vascular risk factors: a systematic review and meta-analysis.2018Journal of the Neurological Sciences
Effect of preoperative loading dose ticagrelor and clopidogrel on no-reflow phenomenon during intervention in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis.2018Drug Design, Development and Therapy
Drug updated on 5/29/2023

More on this drug: Clinical Trials